Testing focused ultrasound with bevacizumab for recurrent glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study combines a focused ultrasound device (NaviFUS) with a drug called bevacizumab to treat glioblastoma that has come back after standard treatment. The combination may help the drug reach the tumor better and improve treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with glioblastoma and it has come back after previous treatment with radiation and temozolomide chemotherapy.
- Your tumor is at least 10 mm wide and is located at least 30 mm below the skull surface.
- It has been at least 12 weeks since your last radiation treatment.
- If you take steroids, your dose has been stable for at least 7 days before the study starts.
- You have not had bevacizumab (Avastin) or a similar drug before.
- You are able to have your hair shaved and have a peripheral IV line placed, and you can lie still for the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests whether focused ultrasound can safely open the blood-brain barrier to help your chemotherapy work better. It is for people with glioblastoma who have already completed standard surgery and chemo-radiation and are now on maintenance chemo.
This trial tests a device that opens the blood-brain barrier using ultrasound, allowing chemotherapy to reach the brain tumor better. It compares this approach to standard chemotherapy for people whose glioblastoma has returned.
This trial tests a new treatment called sonodynamic therapy that uses sound waves and a special drug to target brain tumors that have come back. It aims to see if this approach is safe and can shrink tumors in people who are eligible for surgery.
This trial tests a new way of treating recurrent glioblastoma that has a specific genetic feature called mismatch repair deficiency. It uses focused ultrasound to help the immunotherapy drug pembrolizumab work better against the tumor.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
Hear when a new GBM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.